Zimenkov Danila, Zhuravlev Vyacheslav, Ushtanit Anastasia, Filippova Marina, Semenova Uliana, Solovieva Natalia, Sviridenko Maria, Khakhalina Anastasia, Safonova Svetlana, Makarova Marina, Gordeeva Elizaveta, Guselnikova Elena, Schwartz Yakov, Stavitskaya Natalia, Yablonsky Peter
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation, 191036 Saint-Petersburg, Russia.
Int J Mol Sci. 2024 Dec 8;25(23):13200. doi: 10.3390/ijms252313200.
Infections caused by nontuberculous mycobacteria (NTM) are rising globally throughout the world. The number of species isolated from clinical samples is steadily growing, which demands the implementation of a robust diagnostic method with wide specificity. This study was carried out in in 2022-2024 in three clinical antituberculosis centers in the biggest cities of Russia: Moscow, Saint Petersburg, and Novosibirsk. We developed the DNA hybridization assay 'Myco-biochip' that allows the identification of 79 mycobacterial species and analyzed 3119 samples from 2221 patients. Sixty-eight mycobacterial species were identified in clinics, including the three novel species phylogenetically related to , , and . The identification of a close relative of adds to the existence of separate clade between , complexes and other slow-growing , which supports the thesis against the splitting of into five separate genera. Adding to the list of potentially pathogenic species, we identified and , which were previously described as natural habitats. The diversity of acid-fast bacilli identified in TB-suspected persons was not limited to the genus and also includes species from genera , , , , and of the order . The revealed bacterial diversity in patients with suspected NTM-diseases requires the implementation of relevant species identification assays as the first step in the laboratory diagnostic pipeline.
非结核分枝杆菌(NTM)引起的感染在全球范围内呈上升趋势。从临床样本中分离出的菌种数量在稳步增加,这就需要采用一种具有广泛特异性的强大诊断方法。本研究于2022年至2024年在俄罗斯最大城市的三个临床抗结核中心进行:莫斯科、圣彼得堡和新西伯利亚。我们开发了DNA杂交检测方法“Myco - 生物芯片”,该方法能够鉴定79种分枝杆菌,并分析了来自2221名患者的3119份样本。在临床中鉴定出了68种分枝杆菌,包括与、和在系统发育上相关的三个新菌种。对的一个近亲的鉴定增加了在、复合体与其他缓慢生长的之间存在单独进化枝的证据,这支持了反对将分为五个独立属的论点。在潜在致病菌种列表中,我们鉴定出了和,它们之前被描述为自然栖息地。在疑似结核病患者中鉴定出的抗酸杆菌的多样性不仅限于属,还包括来自目、、、、属的菌种。在疑似NTM疾病患者中发现的细菌多样性要求在实验室诊断流程的第一步实施相关的菌种鉴定检测。